{"id":1931,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2020-06-12","marketCap":5636.91748046875,"name":"Vaxcyte Inc","phone":"16508370111","outstanding":95.1500015258789,"symbol":"PCVX","website":"https://vaxcyte.com/","industry":"Biotechnology"},"price":57.9325,"year":2023,"month":12,"day":14,"weekday":"Thursday","title":"Corporate Governance Practices of Vaxcyte Inc Stock","date":"2023-12-14","url":"/posts/2023/12/14/PCVX","content":[{"section":"Board Composition","text":"Vaxcyte Inc's board of directors consists of highly experienced and qualified individuals from diverse backgrounds. The board includes leaders with expertise in biotechnology, finance, and healthcare. This composition ensures a well-rounded perspective and effective decision-making."},{"section":"Independence","text":"The majority of Vaxcyte Inc's board members are independent directors, meaning they have no significant financial or personal relationships with the company or its executives. This independence helps in safeguarding shareholders' interests and mitigating potential conflicts of interest."},{"section":"Committees","text":"Vaxcyte Inc has established various committees within its board, such as the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee. These committees play crucial roles in overseeing financial reporting, executive compensation, and the selection of board members."},{"section":"Executive Compensation","text":"Vaxcyte Inc maintains a transparent and performance-based executive compensation system. The compensation of executives is linked to the company's financial and operational performance, aligning their interests with those of the shareholders. This structure motivates executives to drive long-term value creation."},{"section":"Disclosure Practices","text":"Vaxcyte Inc follows a policy of transparent disclosure. The company provides comprehensive information about its financial performance, governance practices, and risk factors in its annual reports, proxy statements, and other regulatory filings. This promotes transparency and allows shareholders to make informed decisions."},{"section":"Shareholder Rights","text":"Vaxcyte Inc respects and protects the rights of its shareholders. The company allows shareholders to vote on key matters, such as the election of directors and significant corporate transactions. The board also considers shareholder input and engages in dialogue to address their concerns."},{"section":"Ethics and Compliance","text":"Vaxcyte Inc upholds high ethical standards and promotes a culture of compliance. The company has implemented a code of conduct and ethics that guides the behavior of its directors, officers, and employees. Regular training programs and internal controls help ensure adherence to ethical practices."},{"section":"Conclusion","text":"Vaxcyte Inc demonstrates strong corporate governance practices, characterized by a well-composed board, independent directors, transparent executive compensation, and a commitment to shareholder rights. These practices contribute to the company's overall transparency, accountability, and long-term value creation."}],"tags":["CrossOver100","Long","Biotechnology"],"news":[{"category":"company","date":1702431060,"headline":"Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), Autolus Therapeutics (AUTL) and Vaxcyte (PCVX)","id":124499911,"image":"","symbol":"PCVX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3254667496"},{"category":"company","date":1702045256,"headline":"We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely","id":124396232,"image":"https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","symbol":"PCVX","publisher":"Yahoo","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...","url":"https://finance.yahoo.com/news/were-hopeful-vaxcyte-nasdaq-pcvx-142056073.html"},{"category":"company","date":1701990788,"headline":"Mizuho Initiates Coverage of Vaxcyte (PCVX) with Buy Recommendation","id":124375409,"image":"","symbol":"PCVX","publisher":"Fintel","summary":"","url":"https://fintel.io/news/mizuho-initiates-coverage-of-vaxcyte-pcvx-with-buy-recommendation-48"},{"category":"company","date":1701916500,"headline":"Vaccine Player Vaxcyte Can Potentially Disrupt Pfizer's 20-Plus-Year Near Monopoly, Says Analyst","id":124374750,"image":"","symbol":"PCVX","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3246460529"},{"category":"company","date":1701832560,"headline":"Vaxcyte’s Promising Market Disruption and De-risked Profile Spurs Buy Rating","id":124368082,"image":"","symbol":"PCVX","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3244652981"},{"category":"company","date":1701832440,"headline":"Vaxcyte initiated with a Buy at Mizuho","id":124368083,"image":"","symbol":"PCVX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3244647402"},{"category":"company","date":1701754620,"headline":"Vaxcyte's pneumococcal shot shows safety profile comparable to Pfizer's Prevnar 20","id":124304198,"image":"","symbol":"PCVX","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3242031496"},{"category":"company","date":1701732900,"headline":"VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate","id":124293381,"image":"https://s.yimg.com/ny/api/res/1.2/TWxJFBqgKq38_fl8Vqrihw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD00NjI-/https://media.zenfs.com/en/globenewswire.com/4e1ad97f4020a90d11d9a97e343c7ee3","symbol":"PCVX","publisher":"Yahoo","summary":"-- In the Study, VAX-24 Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) at all Doses Studied -- -- All 24 Serotypes of VAX-24 at Conventional 2.2 mcg PCV Dose Met or Exceeded Regulatory Immunogenicity Standards -- -- Results Confirm Potential of Carrier-Sparing, Cell-Free Platform Technology Underlying VAX-24 -- -- Topline Data from the VAX-24 Phase 3 Pivotal Non-Inferiority Study in Adults Expected in 2025 -- SAN CARLOS, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Va","url":"https://finance.yahoo.com/news/vax-24-phase-1-2-233500579.html"},{"category":"company","date":1701668220,"headline":"Vaxcyte says VAX-24 proof-of-concept results published in The Lancet","id":124304200,"image":"","symbol":"PCVX","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3241229611"}]}